Cargando…

Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study

We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a univer...

Descripción completa

Detalles Bibliográficos
Autores principales: Pambet, Mathilde, Delabaere, Amélie, Figuier, Claire, Lambert, Céline, Comptour, Aurélie, Rouzaire, Marion, Gallot, Denis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964196/
https://www.ncbi.nlm.nih.gov/pubmed/36836056
http://dx.doi.org/10.3390/jcm12041521
_version_ 1784896443004223488
author Pambet, Mathilde
Delabaere, Amélie
Figuier, Claire
Lambert, Céline
Comptour, Aurélie
Rouzaire, Marion
Gallot, Denis
author_facet Pambet, Mathilde
Delabaere, Amélie
Figuier, Claire
Lambert, Céline
Comptour, Aurélie
Rouzaire, Marion
Gallot, Denis
author_sort Pambet, Mathilde
collection PubMed
description We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a university hospital. The study included 195 patients, comprising 144 compliant protocols. Pain was statistically more frequent in the non-compliance group (92.2% vs. 62.5%, p < 0.001), and when a midwife was unavailable (15.7% vs. 0.7%, p < 0.001). A multivariable analysis found factors of good response (defined as going into labor before the administration of the median number of tablets, i.e., six) to be an indication for PROM (OR: 12.03, 95% CI: 5.42–26.71), and gestational age at induction (OR: 1.54, 95% CI: 1.19–2.01), independently of BMI, initial Bishop score, and parity. Patients with pain who were able to follow the protocol delivered 9 h earlier than patients with pain who interrupted the protocol and 16 h earlier than patients who experienced no pain. We identified two key elements that favored compliance: (i) providing the next tablet in advance; and (ii) offering patients early epidural analgesia when in pain in order to continue the protocol and go into labor promptly.
format Online
Article
Text
id pubmed-9964196
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99641962023-02-26 Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study Pambet, Mathilde Delabaere, Amélie Figuier, Claire Lambert, Céline Comptour, Aurélie Rouzaire, Marion Gallot, Denis J Clin Med Article We set out to identify factors of non-compliance with a protocol for the oral administration of misoprostol 25 µg (Angusta(®)) every 2 h (up to eight tablets), for the induction of labor (IOL). We conducted a retrospective study on IOL at term, on singleton pregnancies from 2019 to 2021, in a university hospital. The study included 195 patients, comprising 144 compliant protocols. Pain was statistically more frequent in the non-compliance group (92.2% vs. 62.5%, p < 0.001), and when a midwife was unavailable (15.7% vs. 0.7%, p < 0.001). A multivariable analysis found factors of good response (defined as going into labor before the administration of the median number of tablets, i.e., six) to be an indication for PROM (OR: 12.03, 95% CI: 5.42–26.71), and gestational age at induction (OR: 1.54, 95% CI: 1.19–2.01), independently of BMI, initial Bishop score, and parity. Patients with pain who were able to follow the protocol delivered 9 h earlier than patients with pain who interrupted the protocol and 16 h earlier than patients who experienced no pain. We identified two key elements that favored compliance: (i) providing the next tablet in advance; and (ii) offering patients early epidural analgesia when in pain in order to continue the protocol and go into labor promptly. MDPI 2023-02-14 /pmc/articles/PMC9964196/ /pubmed/36836056 http://dx.doi.org/10.3390/jcm12041521 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pambet, Mathilde
Delabaere, Amélie
Figuier, Claire
Lambert, Céline
Comptour, Aurélie
Rouzaire, Marion
Gallot, Denis
Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title_full Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title_fullStr Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title_full_unstemmed Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title_short Factors of Non-Compliance with a Protocol for Oral Administration of Misoprostol (Angusta(®)) 25 Micrograms to Induce Labor: An Observational Study
title_sort factors of non-compliance with a protocol for oral administration of misoprostol (angusta(®)) 25 micrograms to induce labor: an observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964196/
https://www.ncbi.nlm.nih.gov/pubmed/36836056
http://dx.doi.org/10.3390/jcm12041521
work_keys_str_mv AT pambetmathilde factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT delabaereamelie factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT figuierclaire factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT lambertceline factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT comptouraurelie factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT rouzairemarion factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy
AT gallotdenis factorsofnoncompliancewithaprotocolfororaladministrationofmisoprostolangusta25microgramstoinducelaboranobservationalstudy